The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Athena is also exploring the use of this technology for expanded carrier screening
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Subscribe To Our Newsletter & Stay Updated
